Annuncio • May 22
Vectus Biosystems Limited has filed a Follow-on Equity Offering. Vectus Biosystems Limited has filed a Follow-on Equity Offering.
Security Name: Odinary Shares
Security Type: Common Stock
Transaction Features: Subsequent Direct Listing Reported Earnings • Mar 04
First half 2026 earnings released: AU$0.014 loss per share (vs AU$0.021 loss in 1H 2025) First half 2026 results: AU$0.014 loss per share (improved from AU$0.021 loss in 1H 2025). Revenue: AU$5.5k (down 99% from 1H 2025). Net loss: AU$731.7k (loss narrowed 34% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Board Change • Oct 23
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Linda Walters was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Oct 09
Vectus Biosystems Limited, Annual General Meeting, Nov 26, 2025 Vectus Biosystems Limited, Annual General Meeting, Nov 26, 2025. New Risk • Aug 31
New major risk - Negative shareholders equity The company has negative equity. Total equity: -AU$257k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$830k free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$257k). Revenue is less than US$1m (AU$478k revenue, or US$313k). Market cap is less than US$10m (AU$4.43m market cap, or US$2.90m). Reported Earnings • Aug 31
Full year 2025 earnings released: AU$0.033 loss per share (vs AU$0.044 loss in FY 2024) Full year 2025 results: AU$0.033 loss per share (improved from AU$0.044 loss in FY 2024). Revenue: AU$478.2k (down 58% from FY 2024). Net loss: AU$1.78m (loss narrowed 24% from FY 2024). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings. Board Change • Apr 29
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Linda Walters was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 08
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Linda Walters was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Mar 17
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Linda Walters was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 25
First half 2025 earnings released: AU$0.021 loss per share (vs AU$0.022 loss in 1H 2024) First half 2025 results: AU$0.021 loss per share (improved from AU$0.022 loss in 1H 2024). Revenue: AU$393.7k (down 39% from 1H 2024). Net loss: AU$1.10m (loss narrowed 6.7% from 1H 2024). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Board Change • Jan 29
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Linda Walters was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Dec 23
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Linda Walters was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Dec 20
Vectus Biosystems Limited Appoints Linda Ann Walters as Non-Executive Director of the Board Vectus Biosystems Limited announced the appointment of Linda Ann Walters as a non-executive director of the board of the company, effective from 20 December 2024. Linda Walters has a strong operational, commercial and technical background across a number of life sciences, biotechnologies and health care companies. She has held senior leadership positions supporting both listed and unlisted Australian companies for over 25 years. Linda has made a significant contribution to Vectus since its inception and public listing, and has a detailed knowledge of the Company's technologies, intellectual property (IP) and commercialization programme. Her expertise spans the fields of human resources, finance, information technology and the commercialization of IP. Linda has served with Regional Health Care Group and Henry Schein in a number of senior leadership roles, and was instrumental in developing Vectus' operational and commercial capabilities. Board Change • Nov 25
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Annuncio • Oct 08
Vectus Biosystems Limited, Annual General Meeting, Nov 27, 2024 Vectus Biosystems Limited, Annual General Meeting, Nov 27, 2024. Reported Earnings • Oct 05
Full year 2024 earnings released: AU$0.044 loss per share (vs AU$0.072 loss in FY 2023) Full year 2024 results: AU$0.044 loss per share (improved from AU$0.072 loss in FY 2023). Revenue: AU$1.14m (down 16% from FY 2023). Net loss: AU$2.34m (loss narrowed 32% from FY 2023). Products in clinical trials Phase I: 1 Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. New Risk • Sep 07
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.1m free cash flow). Earnings have declined by 2.5% per year over the past 5 years. Revenue is less than US$1m (AU$1.1m revenue, or US$760k). Market cap is less than US$10m (AU$4.26m market cap, or US$2.84m). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change). Board Change • Feb 05
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Annuncio • Oct 05
Vectus Biosystems Limited, Annual General Meeting, Nov 22, 2023 Vectus Biosystems Limited, Annual General Meeting, Nov 22, 2023, at 15:00 AUS Eastern Standard Time. Reported Earnings • Sep 01
Full year 2023 earnings released: AU$0.072 loss per share (vs AU$0.12 loss in FY 2022) Full year 2023 results: AU$0.072 loss per share (improved from AU$0.12 loss in FY 2022). Revenue: AU$1.35m (up 4.2% from FY 2022). Net loss: AU$3.45m (loss narrowed 14% from FY 2022). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Board Change • Jul 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. New Risk • Jun 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$4.1m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (AU$1.9m revenue, or US$1.3m). Market cap is less than US$100m (AU$22.9m market cap, or US$15.3m). Reported Earnings • Feb 25
First half 2023 earnings released: AU$0.05 loss per share (vs AU$0.08 loss in 1H 2022) First half 2023 results: AU$0.05 loss per share (improved from AU$0.08 loss in 1H 2022). Revenue: AU$579.3k (up AU$579.2k from 1H 2022). Net loss: AU$2.14m (loss narrowed 16% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 7% per year. Annuncio • Dec 02
Vectus Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 3.65307 million. Vectus Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 3.65307 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,566,337
Price\Range: AUD 0.8
Discount Per Security: AUD 0.04
Transaction Features: Subsequent Direct Listing Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (5 non-independent directors). Non-Executive Director Susan Pond was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Annuncio • Oct 12
Vectus Biosystems Limited, Annual General Meeting, Nov 23, 2022 Vectus Biosystems Limited, Annual General Meeting, Nov 23, 2022, at 11:00 AUS Eastern Standard Time. Location: 26-34 Dunning Avenue, Rosebery Roseberry New South Wales Australia Annuncio • Sep 14
Vectus Biosystems Limited Announces Completion of Phase Ia for VB0004 Vectus Biosystems Limited announced the completion of the third and last of the three planned cohorts in the Multiple Ascending Dose (M.A.D.) segment of its first-in-human trial: "A phase I/Ib, first-time-in-human, single centre, double-blind, randomized, placebo-controlled, dose escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses of VB0004 administered orally to healthy volunteers; and to patients with mild to moderate hypertension with low cardiovascular risk", which has been reviewed by the Trial Safety Review Committee (Committee). In this cohort of normal healthy subjects who received a 100mg dose of VB0004 for 14 consecutive days no significant adverse events were reported. This study group has further enhanced the impressive safety record of VB0004. The interim pharmacokinetics (PK) analysis confirms again thatthe time to achieve the maximal concentration (Tmax) of VB0004 occurred six to eight hours after dosing and that the plasma half-life (the time taken for the plasma concentration of VB0004 to decrease by 50%) was 10 to 15 hours on both Days 1 and 14. The data also suggests that little to no accumulation of VB0004 occurred with time in normal individuals. This data reinforces the previous evidence that VB0004 will be amenable to once daily dosing, a desirable feature in medications for chronic conditions such as hypertension, heart failure, kidney failure and pulmonary fibrosis. To-date the Committee has reviewed data from all five planned Single Ascending Dose (S.A.D.) cohorts as well as all three planned M.A.D. cohorts. This Phase Ia trial has established an impressive safety profile for VB0004 with a maximum tolerated single dose of 300mg and no significant adverse eventsseen in M.A.D. studies at 10mg, 30mg or 100mg administered daily over a 14-day period. Also established are consistent PK of six to eight hours to achieve maximal plasma concentration and a half life in excess of 10 hours. The Committee has now given permission for the Phase Ib section of the trial to commence. In this section of the clinical trial patients with uncomplicated hypertension will be treated for 28 days at a dose of 30mg of VB0004 per day. The trial is registered on the Clinical Trials Protocol Registration and Results Systems (ClinicalTrials.gov) and has been provided with the identifier NCT04925050. Protocol details may be found using this number on the ClinicalTrials.gov public website. Reported Earnings • Sep 01
Full year 2022 earnings released: AU$0.12 loss per share (vs AU$0.15 loss in FY 2021) Full year 2022 results: AU$0.12 loss per share (up from AU$0.15 loss in FY 2021). Revenue: AU$1.30m (up AU$1.22m from FY 2021). Net loss: AU$3.99m (loss narrowed 6.7% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Annuncio • Aug 08
Vectus Biosystems Limited Announces Completion of Second M.A.D. Study for Vb0004 Vectus Biosystems Limited announced that the second of the three planned cohorts in the Multiple Ascending Dose (M.A.D.) segment of its first-in-human trial: "A phase I/Ib, first-time-in-human, single centre, double-blind, randomized, placebo-controlled, dose escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses of VB0004administered orally to healthy volunteers; and to patients with mild to moderate hypertension with low cardiovascular risk", has been reviewed by the Trial Safety Review Committee (Committee). In this cohort, which received a 30mg dose of VB0004 for 14 consecutive days, no significant adverse events were reported, adding again to the impressive safety record of VB0004. The interim PK analysis confirmed that the time to achieve the maximal concentration (Tmax) of VB0004 occurred six to eight hours after dosing, and the plasma half-life (the time taken for the plasma concentration of VB0004 to decrease by 50%) was between 10 and 15 hours on both Days 1 and 14. The data also suggests that little to no accumulation of VB0004 occurred with time, in normal individuals, adding to the safety profile of VB0004. This data provides further evidence that VB0004 will be amenable to once daily dosing, a desirable feature in medications for chronic conditions such as hypertension, heart failure, kidney failure and pulmonary fibrosis. To-date the Committee has reviewed data from all five planned Single Ascending Dose (S.A.D.) cohorts as well as two of the three planned M.A.D. cohorts. The study has established an impressive safety profile for VB0004 with a maximum tolerated single dose of 300mg, and no significant adverse events seen in M.A.D. studies at 10mg and 30mg administered daily over a 14-day period. Also established are the consistent six to eight hours to achieve maximal plasma concentration and a half-life in excess of 10 hours. The Committee has now given permission for the third and final M.A.D. cohort to proceed, in which participants will receive 100mg per day for 14 days. Four participants have been enrolled and commenced the 14-day study. Annuncio • May 26
Vectus Biosystems Limited Announces Completion of Final Single Ascending Dose Study and First Multiple Ascending Dose Study for VB0004 Vectus Biosystems Limited announced that all five of the planned cohorts in the Single Ascending Dose (S.A.D.) segment of its first-in-human trial: "A phase I/Ib, first-time-in-human, single centre, double-blind, randomized, placebo-controlled, dose escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses of VB0004 administered orally to healthy volunteers; and to patients with mild to moderate hypertension with low cardiovascular risk", have been reviewed by the Trial Safety Review Committee (Committee). The results of the 2mg, 10mg, 30mg, 100mg and 300mg doses of VB0004 have now been reviewed by the Committee. Of greatest significance, no adverse events have been observed at any of the five doses of VB0004 studied to-date. Further, the latest dose of 300mg has added very significantly to the therapeutic safety margin for VB0004. The interim pharmacokinetic (PK) analysis confirmed that the time to achieve its maximal concentration (Tmax) after dosing occurred at six to eight hours and the plasma half-life (the time taken for the plasma concentration of VB0004 to decrease by 50%) was 17 to 17.5 hours. This preliminary data provides further evidence that VB0004 will be amenable to once daily dosing, a desirable feature in medications for chronic conditions such as hypertension, heart failure, kidney failure and pulmonary fibrosis. The Committee also reviewed the outcomes for the first Multiple Ascending Dose (M.A.D.) cohort in which 10mg of VB0004 was administered daily for 14 days. Again, there were no adverse events adding to the impressive safety profile of VB0004. The Committee has now given permission for the second M.A.D. cohort to proceed and the first three participants have been enrolled. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Susan Pond was the last independent director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annuncio • Feb 21
Vectus Biosystems Limited Announces Fourth of the Five Planned Cohorts in the Single Ascending Dose Segment of Its First-In-Human Tria Vectus Biosystems Limited announced that the fourth of the five planned cohorts in the Single Ascending Dose (S.A.D.) segment of its first-in-human trial: "A phase I/Ib, first-time-in-human, single centre, double-blind, randomized, placebo-controlled, dose escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses of VB0004 administered orally to healthy volunteers; and to patients with mild to moderate hypertension with low cardiovascular risk", has been reviewed by the Trial Safety Review Committee (Committee). To-date, the results of the 2mg, 10mg, 30mg and 100mg doses of VB0004 have been reviewed by the Committee. Most significantly, no adverse events have been observed at any of the four doses of VB0004 studied to-date and the latest dose of 100mg has added materially to the therapeutic safety margin for VB0004. The lack of adverse events has allowed the Committee to give permission to proceed with three further studies, being: the last S.A.D. Cohort, which has a planned dose of 300mg of VB0004; the Food Effect study, in which Cohort 3 subjects will return and have pharmacokinetic (PK) measurements undertaken when VB0004 is taken following food ingestion; and the first Multiple Ascending Dose (M.A.D.) Cohort, which will receive a dose of 10mg of VB0004 per day for 14 days. Thus, this approval represents a significant milestone in VB0004's trajectory. The interim PK analysis showed that the maximum plasma concentration of VB0004 increased with the increased dose. The time to achieve its maximal concentration (Tmax) after dosing did not change, but the plasma half-life (the time taken for the plasma concentration of VB0004 to decrease by 50%) increased to 17-17.5 hours. This preliminary data provides further evidence that VB0004 will be amenable to once daily dosing, a desirable feature in medications for chronic conditions such as hypertension, heart failure, kidney failure and pulmonary fibrosis. The trial is registered on the Clinical Trials Protocol Registration and Results Systems and has been provided with the identifier NCT04925050. Annuncio • Nov 29
Vectus Biosystems Limited Announces Third S.A.D. Group Reviewed by Trial Safety Review Committee Vectus Biosystems Limited announced that the third of the five planned cohorts in the Single Ascending Dose (S.A.D.) segment of its first in human trial "A phase I/Ib, first-time-in-human, single centre, double-blind, randomized, placebo-controlled, dose escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses of VB0004 administered orally to healthy volunteers; and to patients with mild to moderate hypertension with low cardiovascular risk" has been reviewed by the Trial Safety Review Committee. The Trial Safety Review Committee, having reviewed the 2mg, 10mg and 30mg doses of VB0004, has now given approval to proceed to the next dose level of 100mg. Importantly, no adverse events were observed at any of the three doses of VB0004 studied to-date. The interim pharmacokinetic (PK) analysis shows that the plasma concentrations of VB0004 increase to maximal concentration (Tmax) approximately eight hours after dosing. Further, VB0004 has a plasma half-life (the time taken for the plasma concentration to decrease by 50%) of 9.5 to 10 hours. These preliminary data suggest that VB0004 will be amenable to once daily dosing, a desirable feature in medications for chronic conditions such as hypertension, heart failure, kidney failure and pulmonary fibrosis. The trial is registered on the Clinical Trials Protocol Registration and Results Systems (ClinicalTrials.gov) and has been provided with the identifier NCT04925050. Recent Insider Transactions Derivative • Nov 17
Independent Non-Executive Chairman exercised options to buy AU$277k worth of stock. On the 9th of November, Ronald Shnier exercised options to buy 200k shares at a strike price of around AU$0.50, costing a total of AU$100k. This transaction amounted to 185% of their direct individual holding at the time of the trade. Since June 2021, Ronald has owned 100.00k shares directly. This was the only transaction from an insider over the last 12 months. Reported Earnings • Sep 02
Full year 2021 earnings released: AU$0.15 loss per share (vs AU$0.13 loss in FY 2020) Full year 2021 results: Net loss: AU$4.28m (loss widened 43% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Annuncio • Aug 25
Vectus Biosystems Limited Announces Successful Completion of First Group in Phase I Human Trial Vectus Biosystems Limited (Vectus or the Company) announced that the first cohort consisting of eight subjects has completed all protocol requirements for the 2mg dose in the Single Ascending Dose (SAD) component of its Phase I/IB trial entitled: The results for this cohort have been reviewed by the trial safety committee and it has been deemed safe to proceed with the next dosage level. The trial is registered on the Clinical Trials Protocol Registration and Results Systems (ClinicalTrials.gov) and has been provided with the identifier NCT04925050. Annuncio • Jun 17
Approval Receives Approval from the Human Research Ethics Committee for Phase I Trial in Australia Vectus Biosystems Limited announce that its Phase I/Ib trial, entitled: "A phase I/Ib, first-time-in-human, single centre, double blind, randomised, placebo-controlled, dose-escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses of VB0004 administered orally to healthy volunteers; and to patients with mild to moderate hypertension
with low cardiovascular risk", has received approval from the Human Research Ethics Committee of the Alfred Hospital, Melbourne. The trial has been registered on the Clinical Trials Protocol Registration and Results Systems (ClinicalTrials.gov), and has been provided with the identifier NCT04925050. The trial may be tracked using this number on the ClinicalTrials.gov public website. The trial site (Nucleus Network, Alfred Campus) will commence the process of recruitment and screening of study subjects in July 2021 for this first-in-human trial. The first component will be what is termed a Single Ascending Dose (SAD) study. In this SAD study a cohort or group of eight subjects (six treated and two placebo) will receive a single nominated dose of VB0004 on one occasion. The dose level is then escalated and the process repeated. This continues until the maximal dose has been reached and this segment of the trial is completed. Is New 90 Day High Low • Dec 03
New 90-day high: AU$1.16 The company is up 17% from its price of AU$0.99 on 04 September 2020. The Australian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period. Annuncio • Nov 20
Vectus Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 7 million. Vectus Biosystems Limited has completed a Follow-on Equity Offering in the amount of AUD 7 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 7,777,778
Price\Range: AUD 0.9
Discount Per Security: AUD 0.036
Transaction Features: Subsequent Direct Listing 